GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lifeline Scientific Inc (LSE:LSI) » Definitions » LT-Debt-to-Total-Asset

Lifeline Scientific (LSE:LSI) LT-Debt-to-Total-Asset : 0.00 (As of Jun. 2016)


View and export this data going back to . Start your Free Trial

What is Lifeline Scientific LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Lifeline Scientific's long-term debt to total assests ratio for the quarter that ended in Jun. 2016 was 0.00.

Lifeline Scientific's long-term debt to total assets ratio stayed the same from Jun. 2015 (0.00) to Jun. 2016 (0.00).


Lifeline Scientific LT-Debt-to-Total-Asset Historical Data

The historical data trend for Lifeline Scientific's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lifeline Scientific LT-Debt-to-Total-Asset Chart

Lifeline Scientific Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 0.05 0.03 - -

Lifeline Scientific Semi-Annual Data
Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 - - - -

Lifeline Scientific LT-Debt-to-Total-Asset Calculation

Lifeline Scientific's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2015 is calculated as

LT Debt to Total Assets (A: Dec. 2015 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2015 )/Total Assets (A: Dec. 2015 )
=0.019/27.868
=0.00

Lifeline Scientific's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2016 is calculated as

LT Debt to Total Assets (Q: Jun. 2016 )=Long-Term Debt & Capital Lease Obligation (Q: Jun. 2016 )/Total Assets (Q: Jun. 2016 )
=0.017/30.398
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lifeline Scientific  (LSE:LSI) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Lifeline Scientific LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Lifeline Scientific's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Lifeline Scientific (LSE:LSI) Business Description

Traded in Other Exchanges
N/A
Address
Lifeline Scientific Inc was incorporated on October 1, 1998. The Company is in the business of delivering, to targeted medical markets, a portfolio of related proprietary technologies, which include devices, solutions, and protocols designed to maximize the use and availability of organs, tissues, and cells. It serves the kidney transplant market today with its LifePort product line, and also sells solutions to service the broader organ transplant industry. The Company operates in North America, Brazil, China and Rest of World.